# Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

> **NCT01435460** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 300 (actual)

## Conditions studied

- Seasonal Allergic Conjunctivitis

## Interventions

- **DRUG:** Loteprednol etabonate 0.2%
- **DRUG:** Olopatadine 0.1%

## Key facts

- **NCT ID:** NCT01435460
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-05
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435460, "Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01435460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*